Jafron Biomedical Hits Day High with Strong 4.59% Intraday Surge

Jafron Biomedical Co., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen a notable increase in its stock price, gaining 4.59% on June 29, 2026. The stock reached an intraday high of CNY 15.93, reflecting a significant uptick in market activity. In terms of performance metrics, Jafron Biomedical's one-day performance stands out against the China Shanghai Composite, which only rose by 1.16% on the same day. However, the company's longer-term performance reveals challenges, with a year-to-date decline of 20.03% and a staggering 82.14% drop over the past five years. Despite these challenges, Jafron Biomedical reported positive results for the first quarter, including a decrease in raw material costs and a strong debtors turnover ratio of 27.4 times. The company also achieved a pre-tax profit of CNY 250.53 million. With a market capitalization of CNY 8,589 million and a return on equity of 15.27%, Jafron Biomedical continues to navigate a complex financial landscape while maintaining a high dividend yield of 4.89%.